Abstract. The mouse anterior pituitary tumor cell line, AtT-20, targets secretory proteins into two distinct intracellular pathways. When the DNA that encodes trypsinogen is introduced into AtT-20 cells, the protein is sorted into the regulated secretory pathway as efficiently as the endogenous peptide hormone ACq'H. In this study we have used double-label immunoelectron microscopy to demonstrate that trypsinogen colocalizes in the same secretory granules as ACTH. In vitro mutagenesis was used to test whether the information for targeting trypsinogen m the secretory granules resides at the amino (NH2) terminus of the protein. Mutations were made in the DNA that encodes trypsinogen, and the mutant proteins were expressed in AtT-20 cells to determine whether intracellular targeting could be altered. Replacing the trypsinogen signal peptide with that of the kappa-immunoglobulin light chain, a constitutively secreted protein, does not alter targeting to the regulated secretory pathway. In addition, deletion of the NH2-terminal "pro" sequence of trypsinogen has virtually no effect on protein targeting. However, this deletion does affect the signal peptidase cleavage site, and as a result the enzymatic activity of the truncated trypsin protein is abolished. We conclude that neither the signal peptide nor the 12 NH2-terminal amino acids of trypsinogen are essential for sorting to the regulated secretory pathway of AtT-20 cells.
Abstract. The mouse anterior pituitary tumor cell line, AtT-20, targets secretory proteins into two distinct intracellular pathways. When the DNA that encodes trypsinogen is introduced into AtT-20 cells, the protein is sorted into the regulated secretory pathway as efficiently as the endogenous peptide hormone ACq'H. In this study we have used double-label immunoelectron microscopy to demonstrate that trypsinogen colocalizes in the same secretory granules as ACTH. In vitro mutagenesis was used to test whether the information for targeting trypsinogen m the secretory granules resides at the amino (NH2) terminus of the protein. Mutations were made in the DNA that encodes trypsinogen, and the mutant proteins were expressed in AtT-20 cells to determine whether intracellular targeting could be altered. Replacing the trypsinogen signal peptide with that of the kappa-immunoglobulin light chain, a constitutively secreted protein, does not alter targeting to the regulated secretory pathway. In addition, deletion of the NH2-terminal "pro" sequence of trypsinogen has virtually no effect on protein targeting. However, this deletion does affect the signal peptidase cleavage site, and as a result the enzymatic activity of the truncated trypsin protein is abolished. We conclude that neither the signal peptide nor the 12 NH2-terminal amino acids of trypsinogen are essential for sorting to the regulated secretory pathway of AtT-20 cells.
T HE intracellular route taken by secretory proteins in eukaryotic cells, from the endoplasrnic reticulum (ER) 1 through the Golgi apparatus and to the cell surface, is well established (56) . Classical secretory cells, such as those of exocrine or endocrine tissues, synthesize, concentrate, and then store one or a few secretory products in large, electrondense, membrane-bound vesicles called secretory granules. Secretion from these specialized secretory cells is triggered by an external signal, and thus has been termed "regulated" secretion (67) . Other ceils that lack specialized secretory granules secrete proteins in an unregulated or constitutive manner. It is generally believed that constitutively secreted proteins traverse the secretory pathway from the ER m the Golgi complex and then are shuttled to the cell surface via small carrier vesicles. No extracellular signal is required m trigger exocytosis of constitutive vesicles.
The mouse anterior pituitary tumor cell line, AtT-20, behaves as a regulated secretory cell in culture. The endogenous prohormone proopiomelanocortin (POMC) is synthesized, glycosylated, and proteolytically processed to mature products including adrenocorticotropic hormone (ACTH). ACTH is concentrated in dense-core secretory granules, and its release is stimulated by secretagogues (47, 48) . In addi-1. Abbreviaaons used in this paper: ER, endoplasmic reticulum; Ksp, kappa signal peptide; LTR, long terminal repeat; POMC, proopiomelanocortin; RSV, Rous sarcoma virus; TG, truncated G (protein). tion, some proteins reach the cell surface of Afr-20 cells via the constitutive secretory route. Both an endogenous retroviral membrane glycoprotein, gpT0 (31) , and the secreted extracellular matrix protein, laminin (8) , are transported exclusively via the constitutive secretory pathway. The mechanism of these intracellular targeting processes is at present unknown, but it may involve recognition of specific sorting signals in the secreted proteins themselves (5) .
Protein targeting to the regulated secretory pathway is apparently conserved among endocrine hormones. When human proinsulin (54) or human growth hormone (52) are stably expressed in AtT-20 cells via DNA-mediated transfection, they are sorted into the regulated secretory pathway at least as well as the endogenous hormone POMC/ACTH. Furthermore, we have recently shown that the exocrine protein, rat anionic trypsinogen, is also selectively targeted to the regulated secretory pathway in the endocrine cell line . Similar evidence has been obtained for human proparathyroid hormone expressed and secreted by a rat pituitary cell line, GH4 (37) , and for human proenkephalin expressed by AtT-20 cells (12) . Thus proteins from different species as well as endocrine and exocrine tissues share the ability m be recognized and targeted to the regulated secretory pathway in AtT-20 cells.
A general approach to elucidating the mechanism of intracellular protein targeting is the use of recombinant DNA techniques (for review, see Garoff [25] ). A cloned gene or cDNA is modified in vitro and, subsequently, the mutated protein is expressed either in vitro or in vivo to address whether a targeting signal has been disrupted. We have taken this approach to attempt to localize the signal responsible for targeting to the regulated secretory pathway. The exocrine protein, trypsinogen, was chosen for this study for several reasons. Inasmuch as the three-dimensional structure of both trypsinogen (22, 45) and trypsin (39, 65) are known, the structural information can be used to design mutations that will involve the surface of the protein (where signal recognition is likely to occur), and that are not likely to drastically alter the overall folding or enzymatic activity of the molecule. If proteins do not fold correctly, their ability to be transported beyond the ER is severely compromised (13, 26, 46, 66) . In addition, because trypsinogen can be converted to trypsin, the proteolytic activity of the secreted mutant protein can be assayed as a very sensitive measure of correct protein folding. If targeting is disrupted but enzymatic activity is maintained, it is more likely that the mutation has altered a targeting signal, and not simply changed the overall structure of the protein, making the signal unrecognizable or inaccessible (58, 69) .
Many intracellular targeting signals are known to be present at the NH2 terminus of the targeted proteins. For example, mitochondrial proteins (20, 36, 38, 40) ; chloroplast proteins (59, 62, 70) , some nuclear proteins (17, 19, 33, 55, 61, 74) , and some proteins targeted to the ER have NH2-terminal transport signals. Most recently, the yeast vacuolar targeting signal of procarboxypeptidase Y has been shown to reside in the NH2-terminal propeptide (42, 68) . In this report data are presented that demonstrate the neither the signal peptide nor the NH2-terminal "pro" peptide of trypsinogen are essential for targeting to the regulated secretory pathway in AtT-20 cells; the intracellular targeting information is apparently not present at the amino terminus of this regulated secretory protein.
Materials and Methods

Materials
The M13 sequencing primer, synthetic DNA linkers, restriction endonucleases, and "I"4 ligase were from New England Biolabs (Beverly, MA). T4 polynucleotide kinase was from Pharmacia Fine Chemicals (Piscataway, NJ). The Klenow fragment of DNA polymerase I was generously provided by P. Walter's Laboratory at University of California, San Francisco (UCSF). 
Cell Culture and Transfections
AtT-20/D-16 cells were grown in Dulbecco's modified Eagle's medium H-21, supplemented with 10% fetal calf serum and penicillin/streptomycin, under a 15% CO2 atmosphere at 37°C. Transfections of AtT-20 cells were by a calcium phosphate precipitation protocol described p~viously (8, 54) . Cotransfections with the selectable plasmid pSV2neo (63) and the nonselectable plasmids coding for the trypsinogen proteins described in the text were performed using 20 ~tg of pSV2neo and 100 ~tg of nonselectable plasmid per 3 x 106 AtT-20 cells. Selection was with 0.25 rng/ml G418 (active drug concentration) (Gibeo Laboratories, Grand Island, NY) for 2 wk after which time individual clones were isolated with cloning rings. Clones were expanded in media containing 0.125 mg/ml G418 and expressing clones were identified using a Western blot assay described previously (8, 10) .
Quantitative Secretion Assay: Calculation of the
Sorting Index
A complete description and derivation of this assay is presented by Moore and Kelly (52) . Briefly, ART-20 cells were metabolically labeled for >-16 h with [35S]cysteine to approach a steady-state labeled condition. The cells were then incubated in normal medium to chase the labeled, constitutively secreted proteins out of the cell. After two 3-h chases, the cells were treated for 3 h with the secretagogue 8-Br-cAMP (5 mM) to stimulate the rate of secretion from the regulated pathway. Wild-type and mutant trypsinogen proteins were immunoprecipitated and analyzed by sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) (8) . The amount of labeled trypsinogen in various samples was quantified by scanning the autoradiograms with an LKB soft laser densitometer (LKB Instruments, Inc., Gaithersburg, MD) or by solubilizing gel slices and counting directly (72) . The immunoprecipitations were quantitative and 80-100 % of the initial radioactivity was recovered in all experiments presented here. The sorting index is the ratio of the increased rate of secretion when the cells are stimulated with 8-Br-cAMP to the steady-state rate of release in the absence of stimulation. As discussed previously (52) , the sorting index is proportional to the probability a nascent protein enters the regulated pathway divided by the probability that it enters the constitutive pathway.
DNA Constructions and In Vitro Mutagenesis
Standard recombinant DNA techniques were used for the following plasmid constructions (48) .
pRSV.':Trypsinogen. To achieve higher trypsinogen expression in AtT-20 cells, the trypsinogen-coding region from pSV2neo: :MTp-trypsinogen was subcloned 3' to the Rous sarcoma virus (RSV) long terminal repeat (LTR) (28) . pRSV-truncated G (TG) (52) was digested with Bgl ll; the Bgl II site was filled in using the Klenow fragment of DNA polymerase i and convened to a Hind III site with a synthetic Hind III linker. The TG gene was then completely removed by digestion with Hind HI; the resulting vector DNA now contained a unique Hind III site just downstream of the RSV LTR. The complete pretrypsinogen DNA was isolated as a Barn HI-Sal I restriction fragment from pSV2neo: :MTp-trypsinogen (8) . The ends of this DNA fragment were also converted to Hind III sites by the use of synthetic Hind III linkers. (The Barn HI site was maintained and was later used in constructing the pRSV: :Ksp-trypsinogen vector.) The trypsinogen fragment was ligated into the RSV LTR vector DNA to obtain the desired pRSV::trypsinogen plasmid. After transformation of Escherichia coli strain DH1 (34), clones harboring plasmids with the desired insert in the correct orientation were identified by restriction mapping.
pRSV.':Ksp Ikypsinogen. Three separate DNA fragments were engineered to create an expression vector coding for trypsinogen with the kappa signal peptide. First, the DNA encoding the MPCU kappa signal peptide (Ksp) was isolated as a Bam HI-Hinc II restriction fragment (43) . The original Pvu II site upstream of the initiating methionine of the Ksp was converted to a Bam HI site in a previous subcloning construction (Matsuuchi and Kelly, manuscript submitted for publication). HinclI cleaves just two amino acids before the end of the signal peptide leaving a blunt end. This blunt end was converted to a Hind HI site using a synthetic linker to allow the use of a convenient Hind IH site in trypsinogen. Second, the trypsinogen-coding sequence was isolated as a Hind llI-Sst I fragment from pTRAP (29) . This DNA fragment contains the entire trypsinogen sequence, but lacks the signal peptide. Ligation of the Ksp Bam HI-Hind III fragment to the trypsinogen Hind III-Sst I fragment creates an in-frame junction between the Ksp and trypsinogen sequences. The Hind III linker contributes six nucleotides that maintain the length of the Ksp, but alters the sequence from Asp and Gly to Gin and Ala. Third, the RSV vector was prepared by partially digesting pRSV: :trypsinogen with Barn HI and a complete digestion with Sst I. The Bam HI-Sst I vector fragment cleaved at the Bam HI site immediately after the RSV LTR was isolated by agarose gel electrophoresis. The three DNA fragments were then ligated (Ksp, Bam HI-Hind III; trypsinogen, Hind llI-Sst I; pRSV, Bam HI-Sst I). The plasmid pRSV: :Ksp trypsinogen was isolated and identified by restriction mapping. The DNA sequence of the Ksp-trypsinogen junction of pRSV::Ksp trypsinogen was confirmed using a double-stranded DNA-sequencing protocol (11) .
pRSV.':Apro trypsin was constructed using a double-primer oligonucleotide mutagenesis protocol (75) . The intronless trypsinogen minigene was subcloned into M13mp8 as described (15) . This single-stranded antisense clone was used as the template for mutagenesis. A 24-nucleotide-long mutagenie primer, TB04, (TB04 = 5'~ATCG-'IqW_JCtA~, was synthesized by the Biomolecular Resource Center at UCSE TB04 spans the desired 24-nucleotide deletion, which when incorporated will lead to the deletion of the 8-amino acid "pro" sequence. Both the mutagenic oligonucleotide TBIM and the M13 sequencing primer (5'GTAAAACGACGC_~-CAGT3') were annealed to the single-stranded antisense trypsinogen M13 template DNA. After extension with the Klenow fragment of DNA polymerase I and ligation with T4 DNA ligase, E. coli strain JM101 was transformed with the DNA. The resulting phage plaques were screened using 32p end-labeled TB04 (14) . 14% of the plaques hybridized to the TB04 oligonucleotide and 4/4 were shown by DNA sequencing to contain the desired Apro trypsin mutation. Double-stranded phage DNA was isolated and the 372-bp Hind III-Xho I restriction fragment containing the Apro trypsin mutation was used to replace the corresponding wild-type restriction fragment in pRSV: :trypsinogen to create pRSV::Apro trypsin. The DNA sequence of the deletion mutation in the expression plasmid was confirmed using a double-stranded supercoiled DNA sequencing protocol (11) .
pRSE':Apro D--N trypsin was constructed by isolating the Eco RI-Xho ! restriction fragment containing the Asp---Asn 102 (D--,-N102) active site mutant from pTRAP D~N102 (29) . This fragment was used to replace the wild-type fragment in pRSV::Apro trypsin using standard subcloning protocols (49) . The D~N102 mutation was confirmed by sequencing the double-stranded plasmid DNA of pRSV::AproD-"N trypsin (11) .
Protein Sequence Analysis
Apro trypsin-expressing cells were labeled overnight with [3SS]cysteine and Apro trypsin was purified from both the medium and cell extract by immunoprecipitation. The radiolabeled Apro trypsin was further purified and concentrated by SDS-PAGE (9, 32). The final pellets were dissolved in 200 I~1 of 0.1% SDS, 0.1 mM EDTA, 0.05 M Tris, pH 7.9, 5 mM DTT, and 0.15 M Natl. The media sample contained ~100,000 cpm and the cell extract sample m30,000 cpm. The sequence analysis was performed on an Applied Biosystems gas-phase sequencer, model 470A, by the Biomolecular Resource Center at UCSE Anilinothiazolinone amino acids were collected at each cycle and [asS] counts per minute were determined.
lmraunoelectron Microscopy
RSV-Tryp cells were removed from their culture dishes using EGTA (5 mM) in PBS. The cells were pelleted in BEEM capsules (Polysciences, Inc., Warrington, PA) by centrifugation at 1,000 rpm for 5 min. The supernatant was removed, and the cell pellet was immediately immersed in a fixation solution containing 4% paraformaldehyde, 0.1% glutaraldehyde, 0.1 M cacodylate buffer (pH 7.4), 4% sucrose, and 15% picric acid (18) . After fixation the cells were embedded in Lowicryl K4M (Polysciences, Inc.) essentially as described (68) .
The Lowicryl-embedded cells were sectioned, collected on nickel grids, and processed as described (2) . The first side of the section was incubated with rabbit anti-ACTH antibodies followed by goat anti-rabbit antibodies coupled to 20-rim gold. This side was then coated with Formvar as described (18) before the second side of the section was incubated with rabbit antitrypsinogen antibodies followed by goat anti-rabbit antibodies coupled to 5-nm gold. After the antibody incubations, the grids were stained with 2% aqueous osmium tetraoxide for 10 min, and then with 2% aqueous uranyl acetate for 5 rain. Finally the grids were examined in a JEOL 100B electron microscope (JEOL USA, Peabody, MA).
Results
Trypsinogen Colocalizes With ACTH in Dense-Core Secretory Granules of AtT-20 Cells
We have previously shown that the exocrine protein rat anionic trypsinogen is targeted to dense-core secretory granules in the endocrine cell line AtT-20 (8). Cell fractionation as well as secretagogue-stimulated release showed that trypsinogen behaves similarly to the endogenous regulated secretory protein POMC/ACTH. To demonstrate directly that trypsinogen is present in the same secretory granule as ACTH, and is not exported through a parallel regulated secretion pathway, we carried out a double-label immunoelectron microscopy experiment.
A human metaUothionein promoter was initially employed to control the expression of trypsinogen in AtT-20 cells (8) . However, the resulting cell line (Tryp-7) expressed insufficient levels of trypsinogen to detect by immunoelectron microscopy. Therefore an expression vector was constructed with the strong promoter-enhancer element, the Rous sarcoma virus (RSV) long terminal repeat (LTR), controlling the expression of trypsinogen. The trypsinogen gene/cDNA (8, 15) was subcloned into pRSV-TG (52) (see Materials and Methods for details) to create pRSV: :trypsinogen. AtT-20 cells were co-transfected with this DNA and pSV2neo as described previously (8) . Clones expressing very high levels of trypsinogen were identified by a Western blot assay, and one, RSV-Tryp, was chosen for all further studies. Using the quantitative secretion assay described previously (52, also see Materials and Methods), we determined that the trypsinogen made and secreted by RSV-Tryp cells was targeted to the regulated secretion pathway with the same efficiency as the trypsinogen expressed from the metallothionein pro- moter (Table I A) . This suggests that although these cells express higher levels of trypsinogen, the amount is apparently not sufficient to observe any saturation of targeting to the regulated secretory pathway. The sorting indices oftrypsinogen and the endogenous hormone POMC/ACTH are very similar, although both are sorted less efficiently than heterologously expressed human growth hormone (52) . The RSV-'fi'yp cell line was then used to perform the double-label immunoelectron microscopy experiment shown in Fig. 1 . A Lowicryl-embedded section of RSV-Tryp cells was stained with rabbit anti-ACI'H antibodies and 20-nm gold coupled to goat anti-rabbit second antibody on one side of the section, and with rabbit anti-trypsinogen antibodies and 5-nm gold coupled to goat anti-rabbit second antibody on the other side of the section (see Materials and Methods for details). This section shows a large number of dense-core secretory granules that stain for both antigens. We did note that in other sections some granules stained for only one antigen or the other. This may be an artifact of the two-sided technique used in that both antigens were not always equally accessible from both sides of the section (see Discussion). We conclude that within the limits of our observations the exocrine protein trypsinogen is targeted to the same population of dense core secretory granules as the endogenous POMC/ACTH.
The 1h/psinogen Signal Peptide Does Not Contain the Secretory Granule Targeting Information
Having thus demonstrated that trypsinogen is targeted to regulated secretory granules, we have begun to dissect the trypsinogen molecule to identify domains in the protein that specify granule localization. To determine whether the signal peptide has any role in protein targeting to the regulated pathway, the trypsinogen signal peptide was replaced with the signal peptide from a constitutively secreted protein, the kappa MPC 11 immunoglobulin light chain (Matsuuchi and Kelly, manuscript submitted for publication). The DNA construct and the corresponding predicted protein sequence are shown in Fig. 2 A. The trypsinogen signal peptide is 15 amino acids in length. Signal peptidase cleaves pretrypsinogen after Ala (-1) 2 and before Phe (+1) to produce trypsinogen. The kappa signal peptide (Ksp) is 28 amino acids long (43) and ends with Gly (-1). The fusion between the Ksp and trypsinogen was made by taking advantage of convenient restriction endonuclease cleavage sites and using a Hind III linker to join the Ksp to the trypsinogen sequences (see Materials and Methods for details). The resultant DNA 2. The amino acid numbering system used here is as follows: Signal peptide residues are assigned negative numbers beginning with -1, just before the cleavage site. The mature sequences are given positive numbers using the chymotrypsinogen system of Hartley (35) . encodes a signal peptide that is the same length as the Ksp, however, the last two amino acids encoded are Gin and Ala, instead of Asp and Gly (see Fig. 2 A) . We have not determined whether these changes affect the accuracy of signal peptidase cleavage. The blot was probed with a specific rabbit anti-rat anionic trypsinogen serum, followed by an L25I-labeled goat anti-rabbit antibody. Trypsinogen and trypsin migrate with apparent molecular weights of ----30,000 and ~29,000, respectively.
The Ksp was cleaved from pretrypsinogen, as judged by comparing wild-type trypsinogen and Ksp trypsinogen by immunoprecipitation and SDS-PAGE (Fig. 2 B) . The secretion properties of Ksp trypsinogen were determined using the quantitative secretion protocol described previously (52, see also Materials and Methods). The secretagogue 8-Br-cAMP stimulated the release of Ksp trypsinogen (Fig. 2 B) and the sorting index calculated from these secretion data did not differ from wild-type trypsinogen (Table I A) . For comparison, the data for a transfected, constitutively secreted protein, the TG protein of vesicular stomatitis virus, is included in Table  I A (52) . There is at least a 30-fold difference in the sorting of TG and the regulated secretory proteins. We conclude from this experiment that the sorting domain required for granule localization in AtT-20 cells is not present in the signal peptide of trypsinogen.
Deletion of the NHrTerminal '~ro" Sequence Does Not Alter Targeting to Secretory Granules
Trypsinogen is secreted from the pancreas as an inactive zymogen. The protease is converted to trypsin when enteropeptidase (50) cleaves off the NH2-terminal eight-amino acid "pro" sequence. This cleavage triggers a local conformational change, whereby the NH2-terminal Ile (+16) of trypsin forms a critical salt bridge with Asp (+194), a residue near the active site (22, 23, 39, 45, 65) . To determine whether the NH2-terminal "pro" sequence is also involved in secretory granule targeting, oligonucleotide-directed mutagenesis was used to precisely delete the "pro" sequence of pretrypsinogen. The DNA construct, (pRSV: :Apro trypsin), and predicted protein sequence are shown in Fig. 3 A. (Details of the mutagenesis are in Materials and Methods.) This construction will direct the synthesis of a protein, which upon correct signal peptidase cleavage and proper protein folding is an active protease. Because this active protease may be detrimental to the cell, a second construct that introduces an active site mutation as well as the "pro" deletion was also made (pRSV:: Apro D~N trypsin). The chosen mutation, Asp--'Asn 102 ( D~N 102) has recently been shown to reduce the enzymatic activity at least four orders of magnitude at neutral pH (16) .
Both pRSV:: Apro trypsin and pRSV: :Apro D--'N trypsin were used to transfect AtT-20 cells, and clones expressing an immunoreactive Apro trypsin were identified by a western blot assay. Fig. 4 shows a Western blot of proteins from the various expressing cell lines. The anti-trypsinogen immunoreactive protein from RSV-Tryp cells comigrates with a rat anionic trypsinogen standard (lanes 1 and 2) . Enteropeptidase digestion (50) Apro trypsin samples were subjected to automated sequence analysis. Anilinothiazolinone amino acids were collected at each cycle and 35S counts per minute were determined. The protein sequence of mature trypsin is shown on top in the one letter amino acid code as in Figs. 2 and 3 ; in addition, C, cysteine, and Y, tyrosine. The deduced sequence of Apro trypsin is shown on the bottom line. The C's are shown in bold lettering to emphasize that these are the only amino acids directly identified using this method.
When the Apro trypsin-and Apro D--'N trypsin-expressing cell lines were exposed to secretagogues, the rate of Apro trypsin secretion was stimulated (Fig. 3 B) . The sorting index calculated for both of these mutant trypsin proteins did not differ from wild-type trypsinogen (Table I B) . We conclude that the granule targeting information is not present in the NHz-terminal "pro" sequence of trypsinogen.
A pro Trypsin Is Not Enzymatically Active
Cells expressing Apro trypsin were viable and unexpectedly indistinguishable from cells expressing trypsinogen or the active site mutant Apro D~N trypsin. Using a variety of assays including binding to bovine pancreatic trypsin inhibitor, hydrolysis of highly sensitive fluorescent peptide substrates (15) , and a gel overlay activity assay (Evnin, L., and C. S. Craik, unpublished results), we were unable to demonstrate any trypsin activity from Apro trypsin-expressing cells. In contrast, the media from trypsinogen expressing cells when digested with enteropeptidase always showed trypsin activity (data not shown). The inactivity could be due to incorrect folding of Apro trypsin. This possibility seems unlikely because this protein is efficiently synthesized, transported, and secreted from AtT-20 cells. Another possible explanation is that the signal peptidase does not cleave in the expected location. If the NH2-terminal Ile (+16) of trypsin is modified (57, 60) , all proteolytic activity is lost. The structural (22, 39, 45, 65) and binding (6, 7) data further suggest that there is a specific binding pocket for the NH2 terminus, such that incorrect cleavage would not allow the active conformation to be achieved.
To determine the NH2-terminal amino acid of Apro trypsin, automated NH2-terminal radiosequence analysis was performed on a [35S]Cys-labeled immunoprecipitated and gel-purified Apro trypsin sample. If the NH2 terminus is Ile (+16) as expected, [35S]Cys counts should be found in cycles 7 and 25 (see Fig. 5 ). If, however, we find peaks of 35S counts at other positions, but separated by the same number of cycles, the altered NH2-terminal sequence can be deduced.
Our sequence analysis of Apro trypsin shows peaks of radioactivity in cycles 3 and 21 (Fig. 5) . These data along with the SDS-PAGE size analysis showing that Apro trypsin is the expected molecular weight, are consistent with the NH2 terminus being at Tyr (+20), four amino acids shorter than expected. Analyses performed on both media and cell extract samples gave similar results, ruling out the possibility of extracellular proteolysis. This result, which places the NH2 terminus at Tyr (+20), is fully consistent with our inability to demonstrate any Apro trypsin activity. We conclude that Apro trypsin is not active because it is proteolytically cleaved (probably by signal peptidase) between Gly (+19) and Tyr (+20) instead of between Ala (-1) and lie (+16) as expected. Furthermore, because the Apro trypsin protein is actually missing the first 12 amino acids of trypsinogen (not just the 8-residue "pro" sequence), we can also conclude that the first 12-NH2-terminal amino acids of trypsinogen are not essential for targeting to the regulated secretory pathway.
Discussion
In this article, we show that the exocrine protein trypsinogen is targeted into the same dense-core secretory granule as the endogenous endocrine protein POMC/ACTH in the anterior pituitary tumor cell line, AtT-20. To identify the protein domain responsible for this intracellular sorting process, we have begun to express mutant trypsinogen proteins to try to alter intracellular targeting. Many other intracellular targeting signals are located at the NH2 terminus of the targeted protein. For example, in procarboxypeptidase Y, the vacuolar targeting signal resides in the NH2-terminal propeptide (42, 69) . In contrast, neither the extreme NH2-terminal signal sequence of pretrypsinogen nor the NH2-terminal "pro" domain of trypsinogen are required for targeting to the regulated secretory pathway in AtT-20 cells.
POMC/ACTH and trypsinogen were colocalized in densecore secretory granules using a double immunocytochemical-staining procedure with antibodies specific for POMC/ ACTH and trypsinogen. This technique involves reacting each primary antibody with only one side of a section, and using different-sized gold particles, coupled to secondary antibodies, to detect each antigen separately. Although we found granules that stained for only a single antigen when using this two-sided technique, we do not believe this is significant. Control experiments in which the same primary antibody was used on both sides of the grid, indicated that all granules were not equally accessible from both sides of the section (see discussion in Bendayan [3] ). This seems reasonable since the sections are of nearly the same thickness (800 ~,) as the diameter of individual secretory granules (diam = 1,000/~), and therefore many granules should be accessible from only one side of the section.
Recently, Fumagalli and Zanini (24) showed that mixed somatomammotrophic cells of cow pituitary (which express both growth hormone and prolactin), can package their hormones into separate secretory granules as well as mixed within the same granule. Interestingly, they also found some granules in which the hormones were segregated into distinct domains within the secretory granules. They suggested that mechanisms exist within somatomammotrophic cells for sorting growth hormone and prolactin into separate granules. Bassetti et al. (1) have presented morphologic evidence for mixed packaging of growth hormone and prolactin into the secretory granules of human pituitary tumors. They also noted that in one tumor they saw separate growth hormone containing granules as well as mixed granules. In contrast, we have no compelling evidence that AtT-20 cells have the ability to distinguish between different regulated secretory proteins; POMC/ACTH and trypsinogen appear to be targeted to secretory granules indistinguishable by both the biochemical (8) and morphologic criteria.
Our finding that replacing the trypsinogen signal peptide with the signal peptide from a constitutive protein does not alter targeting to secretory granules was not unexpected. NH2-terminal signal peptides are known to be responsible for signal recognition particle dependent ER targeting (for review, see Walter et al. [73] ). Once the nascent polypeptide is inserted into the ER membrane, signal peptidase makes a specific cleavage that removes the signal peptide (21, 41, 51) , probably co-translationally (4, 27) . The signal peptide could only be involved in granule targeting if the initial interaction between the regulated secretory protein and the sorting apparatus takes place in the ER. Protein sorting into the regulated secretory pathway is thought to be a post-Golgi apparatus event (44) , and the data presented here are consistent with this view.
In designing our trypsinogen mutation strategy, we have relied on the structural data available for both trypsinogen (22, 45) and trypsin (39, 65) . Inasmuch as the conversion of trypsinogen to trypsin involves predominantly local structural changes, we reasoned that deleting the "pro" sequence would l~rmrb the protein structure to such a small extent that the mutant protein would still be transported beyond the ER to the cell surface. Similarly, although the active site mutation reduces the proteolytic activity at least four orders of magnitude at neutral pH (16), the three-dimensional structure of the D---N102 mutant protein is virtually identical to the wild-type protein (64) . The kinetics of intracellular transport of both the Apro and Apro D--'N variants were slowed about twofold compared with trypsinogen (data not shown); however, the efficiency of sorting into the regulated secretory pathway was not altered (Table I B) . Although the NH2-terminal "pro" domain of trypsinogen does not appear to be required for protein targeting to the regulated secretion pathway in ART-20 cells, the possibility remains that the targeting information is redundant. Either the "pro" sequence or another sequence may be sufficient for protein targeting to the regulated secretion pathway.
Our ability to recover Apro trypsin expressing AtT-20 clones was surprising as we expected pRSV:: Apro trypsin to direct the synthesis of the potent protease, trypsin. Direct protease activity measurements indicated that Apro trypsin was not enzymatically active. NH2-terminal sequence analysis of [35S]Cys-labeled, immunopurified Apro trypsin (Fig. 5) indicated that the first four amino acids of wild-type trypsin were missing from Apro trypsin purified from either radiolabeled cell extracts or media samples. The NH2-terminal Ile (+16) is required for enzymatic activity (57, 60) , and thus this result explains why Apro trypsin is not active. However, it is unclear why this unexpected NH2-terminus is created.
Using a recently published method for predicting signal sequence cleavage sites (71), we calculated weighted scores along the wild-type pretrypsinogen and preApro trypsin sequences. Whereas this calculation method correctly predicts the wild-type pretrypsinogen signal peptide cleavage site between Ala (-1) and Phe (+1), it does not predict the observed cleavage site in preApro trypsin between Gly (+19) and Tyr (+20). Although the score at this position is only the sixth highest along the preApro trypsin sequence, it does occur as a local peak. The weighted calculation method used here relies largely on the sequence of the signal peptide itself; in that this sequence is unchanged in Apro trypsin, the specificity of the proteolytic cleavage must be affected by the sequences COOH-terminal to the signal sequence. The prediction method, however, does not rely on the overall length of the signal peptide. The observed cleavage site of preApro trypsin increases the signal peptide length from 15 to 19 residues which may play a role in cleavage site selection.
The data presented here suggest that the secretory granule targeting information of trypsinogen is not present at the NH2 terminus of the protein, thus the information must be contained within the mature portion of the protein. We have previously compared the primary structures of many different regulated secretory proteins in search of some common targeting sequence; none was found. We suggest that the secretory granule targeting signal might be similar to signal peptides, showing no primary sequence homology, yet displaying functional identity with one another. The common targeting information may interact with a presumptive sorting receptor via a primary sequence-independent association similar to that recently described for peptide antigens with the class II major histocompatibility antigen (30) .
The conventional approach to identify a protein domain containing targeting information is to generate fusion proteins where the presumptive sorting domain is fused to a reporter element. To study sorting in the Golgi complex, however, such fusion proteins must first escape the ER. Recent experiments from this laboratory (Matsuuchi and Kelly, manuscript submitted for publication; 53) have demonstrated that this may be a major limitation. The mutation approach described here offers an alternative strategy. If a mutation causes loss of targeting, it could be due to removal of a targeting signal, or aberrant protein folding that could obscure a targeting signal. If, however, targeting can be disrupted without loss of enzymatic activity, one can make the reasonable argument that the protein structure is intact, and the targeting signal itself has been altered (58, 69) . The knowledge of the three-dimensional structure of trypsinogen may facilitate the design of such catalytically active but incorrectly targeted proteins.
